We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
-6.27%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$332M
AUM Growth
-$842M
Cap. Flow
-$767M
Cap. Flow %
-230.79%
Top 10 Hldgs %
72.35%
Holding
62
New
2
Increased
2
Reduced
10
Closed
34

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$5.31M
2
DNLI icon
Denali Therapeutics
DNLI
+$4.79M
3
PRLD icon
Prelude Therapeutics
PRLD
+$373K
4
KOD icon
Kodiak Sciences
KOD
+$190K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$124M
2
RVMD icon
Revolution Medicines
RVMD
+$120M
3
NUVL
Nuvalent
NUVL
+$52.4M
4
MRUS
Merus
MRUS
+$52.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Miscellaneous 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$46.6M 14.02%
1,317,977
-2,961,487
-69% -$120M
NUVL
2
DELISTED
Nuvalent
NUVL
$31.9M 9.6%
450,000
-670,192
-60% -$52.4M
MRUS
3
DELISTED
Merus
MRUS
$29.5M 8.86%
700,000
-1,200,000
-63% -$52.3M
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$25.5M 7.68%
865,000
-862,388
-50% -$26.9M
ANAB icon
5
AnaptysBio
ANAB
$1.67B
$24.2M 7.27%
1,300,000
– –
XENE icon
6
Xenon Pharmaceuticals
XENE
$5.81B
$20.1M 6.05%
600,000
– –
REPL icon
7
Replimune Group
REPL
$1.46B
$17.5M 5.27%
1,796,341
– –
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$15.6M 4.69%
713,000
-713,000
-50% -$19.7M
CMRX
9
DELISTED
Chimerix, Inc.
CMRX
$15.4M 4.63%
1,810,000
-250,000
-12% -$1.38M
TNGX icon
10
Tango Therapeutics
TNGX
$3.94B
$14.2M 4.28%
10,380,999
– –
ELVN icon
11
Enliven Therapeutics
ELVN
$4.24B
$13.2M 3.97%
671,358
– –
ORIC icon
12
Oric Pharmaceuticals
ORIC
$1.37B
$9.67M 2.91%
1,732,571
– –
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
$9.44M 2.84%
1,189,943
– –
KYMR icon
14
Kymera Therapeutics
KYMR
$9.82B
$8.9M 2.68%
325,000
-100,000
-24% -$3.65M
PRTA icon
15
Prothena Corp
PRTA
$479M
$8.54M 2.57%
690,000
– –
QURE icon
16
uniQure
QURE
$3.38B
$7.95M 2.39%
750,000
– –
LEGN icon
17
Legend Biotech
LEGN
$3.87B
$6.79M 2.04%
200,000
-500,000
-71% -$17.9M
NRIX icon
18
Nurix Therapeutics
NRIX
$2.72B
$6.69M 2.01%
563,067
– –
AMLX icon
19
Amylyx Pharmaceuticals
AMLX
$3.87B
$6.2M 1.86%
1,750,000
– –
SLDB icon
20
Solid Biosciences
SLDB
$1.05B
$4.59M 1.38%
+1,240,700
New +$5.31M
DNLI icon
21
Denali Therapeutics
DNLI
$3.84B
$3.4M 1.02%
+250,000
New +$4.79M
KOD icon
22
Kodiak Sciences
KOD
$2.37B
$2.91M 0.87%
1,035,000
+35,000
+4% +$190K
PRLD icon
23
Prelude Therapeutics
PRLD
$437M
$1.62M 0.49%
2,108,014
+399,827
+23% +$373K
TIL icon
24
Instil Bio
TIL
$51.4M
$1.39M 0.42%
80,125
-275,375
-77% -$5.71M
BOLD
25
Boundless Bio
BOLD
$64.4M
$378K 0.11%
250,000
– –
1
2 3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Boxer Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Boxer Capital Management held 62 positions worth $332M, down 72% from $1.17B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Boxer Capital Management withdrew a net $767M in Q1 2025, closing 34 positions and reducing 10 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Boxer Capital Management opened a new position in Solid Biosciences worth $4.59M.

  • Boxer Capital Management's largest Q1 2025 buy was Solid Biosciences: 1,240,700 shares worth $4.59M.
  • Boxer Capital Management added most to Prelude Therapeutics in Q1 2025, an estimated $373K increase.
  • Boxer Capital Management's biggest Q1 2025 reduction was Revolution Medicines, cutting an estimated $120M.
  • Boxer Capital Management fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $124M.
  • Boxer Capital Management's ten largest holdings make up 72% of its $332M portfolio in Q1 2025.
  • Boxer Capital Management opened 2 new positions and closed 34 in Q1 2025.
  • Boxer Capital Management's portfolio value fell 72% quarter-over-quarter to $332M.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.